Seres Therapeutics (MCRB) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 4, 2022 7:00 AM EDTSER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurrent C. difficile infection, anticipated in Q2 2022
FDA agreement obtained for rolling SER-109 Biologics License Application (BLA) plan; filing completion on track for mid-2022
SER-109 pre-commercialization activities underway, including medical education and payer engagement
Conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS... More
